| 2026-08-13 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-06 | Press release | Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-30 | Press release | Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Sympto |
| 2026-07-23 | Press release | Cytokinetics to Announce Second Quarter Results on August 6, 2026 |
| 2026-07-17 | Press release | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-07 | Press release | Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 |
| 2026-07-07 | Press release | Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 |
| 2026-06-17 | Press release | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-08 | Press release | Cytokinetics Announces Call for Proposals for Annual Corporate Giving Program |
| 2026-06-01 | Press release | Cytokinetics Launches MYQORZO® (aficamten) in European Union, with First Commercial Availability in Germany |
| 2026-05-28 | Transcript | FY26 earnings call transcript |
| 2026-05-27 | Press release | Cytokinetics to Participate in June Investor Conferences |
| 2026-05-27 | Deck | Download
PDF file, (opens in new window) |
| 2026-05-27 | Press release | Cytokinetics to Participate in June Investor Conferences |
| 2026-05-27 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-20 | Press release | Cytokinetics to Hold Annual Meeting of Stockholders |
| 2026-05-20 | Press release | Cytokinetics to Hold Annual Meeting of Stockholders |
| 2026-05-19 | Deck | Corporate Overview
(opens in new window) |
| 2026-05-18 | Press release | Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 2026-05-14 | Press release | Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB) |
| 2026-05-14 | Press release | Cytokinetics to Host Annual Symposium on Contemporary Landscapes in Muscle Biology (CLIMB) |
| 2026-05-12 | Press release | Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference |
| 2026-05-12 | Press release | Cytokinetics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference |
| 2026-05-11 | Press release | Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026 |
| 2026-05-08 | Press release | Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purch |
| 2026-05-08 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-06 | Press release | Cytokinetics Announces Pricing of Upsized Public Offering of Common Stock |
| 2026-05-05 | Press release | Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-05 | Press release | Cytokinetics Announces Proposed Public Offering of Common Stock |
| 2026-05-05 | Press release | Cytokinetics Announces Positive Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Pati |
| 2026-05-05 | Deck | Slides
Open Event Link, PDF file, May 5, 2026, (opens in new window) |
| 2026-05-05 | Deck | Slides
Open Event Link, PDF file, May 5, 2026, (opens in new window) |
| 2026-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-05 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-05-04 | Press release | Cytokinetics to Announce Topline Results from ACACIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients wi |
| 2026-04-28 | Press release | Cytokinetics Announces Ten Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress |
| 2026-04-21 | Press release | Cytokinetics to Announce First Quarter Results on May 5, 2026 |